Press release
Dry Age-Related Macular Degeneration Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | Belite Bio, Inflammx Therapeutics, Ocugen, OliX Pharmaceuti
Dry Age-Related Macular Degeneration Pipeline Analysis
Dry Age-Related Macular Degeneration Pipeline constitutes 70+ key companies continuously working towards developing 80+ Dry Age-Related Macular Degeneration treatment therapies, analyzes DelveInsight.
Dry Age-Related Macular Degeneration Overview:
Age-related macular degeneration (AMD) is a progressive eye disorder that damages the macula, the central part of the retina, resulting in the gradual loss of central vision. It mainly affects individuals over the age of 50 and is a major cause of irreversible vision loss in older adults, particularly in developed countries. First identified over 80 years ago, AMD now affects approximately 170 million people globally, making it the third leading cause of vision impairment worldwide. The disease exists in two forms: dry AMD, which progresses slowly, and wet AMD, which can cause rapid and severe vision loss. Early stages are often symptomless, though signs like drusen (yellow deposits) may be detected during eye exams. In intermediate or advanced stages, patients may experience blurred central vision, dark spots, or difficulty adapting to changes in lighting.
Clinicians use advanced imaging techniques such as fundus photography, fluorescein angiography (FAF), infrared (IR) reflectance, and especially optical coherence tomography (OCT) to diagnose and monitor AMD. Over the past 20 years, spectral-domain OCT (SD-OCT) has become the gold standard for visualizing retinal layers, tracking drusen, geographic atrophy, and other structural changes. Emerging tools like polarization-sensitive OCT (PS-OCT) may further enhance imaging and diagnosis in both research and clinical settings.
Currently, there are no approved treatments for dry AMD. Management focuses on regular monitoring to track progression and intervene early if necessary. Research is actively exploring various therapeutic strategies, including lifestyle modifications, AREDS-based nutritional supplements, anti-inflammatory and anti-toxic agents, visual cycle modulators, complement inhibitors, gene therapy, and cell-based treatments, all aimed at preventing progression or restoring lost vision.
Request for a detailed insights report on Dry Age-Related Macular Degeneration pipeline insights [https://www.delveinsight.com/report-store/dry-age-macular-degeneration-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
"Dry Age-Related Macular Degeneration Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Dry Age-Related Macular Degeneration Therapeutics Market.
Key Takeaways from the Dry Age-Related Macular Degeneration Pipeline Report
*
DelveInsight's Dry Age-Related Macular Degeneration pipeline report depicts a robust space with 70+ active players working to develop 80+ pipeline therapies for Dry Age-Related Macular Degeneration treatment.
*
In June 2024, Stealth BioTherapeutics enrolled the first participant in the Phase III ReNEW clinical trial, which is part of a larger program to evaluate elamipretide as a treatment for dry age-related macular degeneration (AMD). This randomized, double-blind, placebo-controlled study will examine the efficacy, safety, and pharmacokinetics of daily subcutaneous injections of elamipretide.
*
Key Dry Age-Related Macular Degeneration companies such as Belite Bio, Inflammx Therapeutics, Ocugen, OliX Pharmaceuticals, Gensight Biologics, Alkeus Pharmaceuticals, Dobecure, Cognition Therapeutics, Aviceda Therapeutics, Galimedix Therapeutics, Mitotech, Annexon, Inc., NGM Biopharmaceuticals, Johnson & Johnson, Lineage Cell Therapeutics, Astellas Pharma, Regenerative Patch Technologies, Hoffmann-La Roche, Boehringer Ingelheim, ONL Therapeutics, and others are evaluating new drugs for Dry Age-Related Macular Degeneration to improve the treatment landscape.
*
Promising Dry Age-Related Macular Degeneration pipeline therapies in various stages of development include Tinlarebant (LBS-008), XIFLAM, OCU410, OLX301A, GS030, and others.
Dry Age-Related Macular Degeneration Pipeline Analysis
The report provides insights into:
*
The report provides detailed insights into the key companies that are developing therapies in the Dry Age-Related Macular Degeneration Market.
*
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Dry Age-Related Macular Degeneration treatment.
*
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
*
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Dry Age-Related Macular Degeneration market.
Download our free sample page report on Dry Age-Related Macular Degeneration pipeline insights [https://www.delveinsight.com/sample-request/dry-age-macular-degeneration-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Dry Age-Related Macular Degeneration Emerging Drugs
*
Tinlarebant (LBS-008): Belite Bio
*
XIFLAM: Inflammx Therapeutics
*
OCU410: Ocugen
*
OLX301A: OliX Pharmaceuticals
*
GS030: Gensight Biologics
Dry Age-Related Macular Degeneration Companies
Over 70 leading companies are actively working on therapies for Dry Age-related Macular Degeneration (Dry-AMD). Among them, Belite Bio has drug candidates that have progressed to the advanced Phase III stage of development.
DelveInsight's report covers around 80+ products under different phases of clinical development like
*
Late stage products (Phase III)
*
Mid-stage products (Phase II)
*
Early-stage product (Phase I) along with the details of
*
Pre-clinical and Discovery stage candidates
*
Discontinued & Inactive candidates
Dry Age-Related Macular Degeneration pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
*
Intravenous
*
Subcutaneous
*
Oral
*
Intramuscular
Dry Age-Related Macular Degeneration Products have been categorized under various Molecule types such as
*
Monoclonal antibody
*
Small molecule
*
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging Dry Age-Related Macular Degeneration Therapies and Key Companies: Dry Age-Related Macular Degeneration Clinical Trials and advancements [https://www.delveinsight.com/report-store/dry-age-macular-degeneration-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Dry Age-Related Macular Degeneration Pipeline Therapeutic Assessment
- Dry Age-Related Macular Degeneration Assessment by Product Type
- Dry Age-Related Macular Degeneration By Stage
- Dry Age-Related Macular Degeneration Assessment by Route of Administration
- Dry Age-Related Macular Degeneration Assessment by Molecule Type
Download Dry Age-Related Macular Degeneration Sample report to know in detail about the Dry Age-Related Macular Degeneration treatment market @ Dry Age-Related Macular Degeneration Therapeutic Assessment [https://www.delveinsight.com/sample-request/dry-age-macular-degeneration-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Table of Content
1. Report Introduction
2. Executive Summary
3. Dry Age-Related Macular Degeneration Current Treatment Patterns
4. Dry Age-Related Macular Degeneration - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Dry Age-Related Macular Degeneration Late-Stage Products (Phase-III)
7. Dry Age-Related Macular Degeneration Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Dry Age-Related Macular Degeneration Discontinued Products
13. Dry Age-Related Macular Degeneration Product Profiles
14. Dry Age-Related Macular Degeneration Key Companies
15. Dry Age-Related Macular Degeneration Key Products
16. Dormant and Discontinued Products
17. Dry Age-Related Macular Degeneration Unmet Needs
18. Dry Age-Related Macular Degeneration Future Perspectives
19. Dry Age-Related Macular Degeneration Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the Dry Age-Related Macular Degeneration Pipeline Reports Offerings [https://www.delveinsight.com/report-store/dry-age-macular-degeneration-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=dry-agerelated-macular-degeneration-clinical-trials-companies-therapeutic-assessment-therapies-treatment-algorithm-pipeline-analysis-belite-bio-inflammx-therapeutics-ocugen-olix-pharmaceuti]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Dry Age-Related Macular Degeneration Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | Belite Bio, Inflammx Therapeutics, Ocugen, OliX Pharmaceuti here
News-ID: 4105420 • Views: …
More Releases from ABNewswire
Duchenne Muscular Dystrophy Clinical Trials, Companies, Therapeutic Assessment, …
DelveInsight's, "Duchenne Muscular Dystrophy - Pipeline Insight, 2025," report provides comprehensive insights about 75+ companies and 75+ pipeline drugs in Duchenne Muscular Dystrophy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
According to DelveInsight, over 75 leading companies are…
Eczema Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment …
DelveInsight's, "Eczema- Pipeline Insight, 2025" report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Eczema pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Eczema Pipeline constitutes 100+ key companies continuously working towards developing 100+ Eczema treatment…
Exosomes Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatmen …
DelveInsight's, "Exosomes- Pipeline Insight, 2025" report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in Exosomes pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Exosomes Pipeline constitutes 80+ key companies continuously working towards developing 100+ Exosomes treatment…
Head and Neck Cancer Clinical Trials, Companies, Therapeutic Assessment, Therapi …
DelveInsight's, "Head and Neck cancer (HNC) - Pipeline Insight, 2025" report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in Head and Neck cancer (HNC) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Head and Neck Cancer…
More Releases for Dry
Dry Ice Market In-Depth Analysis | Key Participants Dry Ice Corp., Dry Ice UK Lt …
Demand for dry ice is expected to magnify with the development of dry ice machines industry across the globe. Manufacturers in large multinational organizations and private firms have been contributing prominently in the revenue growth of dry ice market. Dry ice being a cost-effective product is expected to bolster its demand across various applications in the near future. Rising number of fire accidents leads to increasing demand for dry ice,…
Dry Screw Vacuum Pumps
Swam Dry vacuum pumps are the latest development in the vacuum pump industry. They offer a number of advantages over traditional vacuum pump designs. Best process gas blowers. There is “NO OIL / NO WATER” contact with the process vapours, which is why they are considered extremely environmentally friendly.
Visit us for more info - http://swamatics.com/ProductDetails.aspx?prod=Process%20Gas%20Blowers/Gas%20Boosters
The definition of a dry vacuum pump is a pump that does not use any…
Dry Bulk Shipping Market to Witness Astonishing Growth during Forecast 2025 | Di …
This report examines Dry Bulk Shipping markets in various aspects of the industry, including market size, market conditions, market trends, forecasts, and more, with brief information on competitors and specific growth by key market drivers. We also provide opportunities. In the report, find a complete Dry Bulk Shipping market analysis broken down by company, region, type, and application.
Some of the key player’s analysis in the Dry Bulk Shipping market:
Diana…
Prepared Dry Foods Market | Key Players : Oregon Freeze Dry, Inc., European Free …
Prepared dry foods are processed food products treated with heat to remove their water content, which makes it inhospitable to most microbes and thus increases the shelf life of the food product. Microbes need water as well as organic content to grow, making the elimination of water a simple and effective way of ensuring the food doesn’t spoil.
For more information on Prepared Dry Foods Market, get free sample report @…
Pet Dry Food 2025 by Key Product - Canned, Pate, Dry Food and International Outl …
The global Pet Dry Food market is valued at million US$ in 2017 and will reach million US$ by the end of 2025, growing at a CAGR of during 2018-2025.
The major manufacturers covered in this report
Ainsworth Pet Nutrition
Big Heart Pet Brands
National Flour Mills
Natural Balance Pet Foods
Rush Direct
Simmons Pet Food
Almo Nature
Aller Petfood
C.J. Foods
Deuerer
Canidae Corp.
Gimborn
Cargill
Crosswind Industries Inc.
Evanger's
Hubbard Feeds
Life's Abundance
Request a Sample at http://www.reportsweb.com/inquiry&RW00012089930/sample
The study objectives of this report are:
To analyze and study…
Dry Concrete Market- What are the Effects of Using Dry Concrete with Detailed Sp …
Market Overview
The report begins from overview of Industry Chain structure, and describes industry environment, then analyses market size and forecast of Dry Concrete by product, region and application, in addition, this report introduces market competition situation among the vendors and company profile, besides, market price analysis and value chain features are covered in this report.
Objective of the Study:
• To outline, classify and estimate the Global Dry Concrete market on the basis…
